DAXOR CORP - 10-Q Summary (Q1 2009)
Business Context and Reporting Period
This report covers the three-month period ended March 31, 2009. Daxor Corporation is a medical device manufacturer focused on the Blood Volume Analyzer (BVA-100) and related diagnostic kits, alongside a cryobanking subsidiary. The company maintains a significant investment portfolio in electric utility stocks, which serves as a critical source of income to offset operating losses.
Key Financial Metrics
| Metric | Q1 2009 | Q1 2008 |
|---|---|---|
| Total Revenues | $434,037 | $420,913 |
| Gross Profit | $281,569 | $268,899 |
| Operating Loss | $(1,114,496) | $(1,268,801) |
| Net Loss | $(1,543,285) | $7,321,008 (Income) |
| Cash & Equivalents (End) | $37,612 | $1,110,018 |
| Total Assets | $62,363,755 | $81,470,591 |
| Total Liabilities | $30,337,903 | $33,363,540 |
| Loans Payable (Margin Debt) | $17,721,817 | $12,017,162 |
Investment Activity: The company reported a net investment loss of approximately $239,000 for the quarter, driven by a $6.26 million mark-to-market loss on short positions, partially offset by $5.07 million in realized gains on securities sales and $987,000 in dividend income.
Material Changes vs. Prior Period
- Profitability Reversal: The company swung from a net income of $7.3 million in Q1 2008 to a net loss of $1.5 million in Q1 2009. This is primarily due to a $6.26 million mark-to-market loss on short positions in 2009, compared to a $2.18 million gain in the same line item in 2008.
- Liquidity Decline: Cash and cash equivalents dropped significantly from $2.55 million at year-end 2008 to $37,612 at March 31, 2009. This decrease was driven by operating cash outflows of $2.97 million and investing outflows of $7.44 million.
- Debt Increase: Margin loans payable increased by approximately $5.7 million to $17.7 million to fund operations and investment activities.
- Operating Revenue Growth: Operating revenues increased 3.1% to $434,037, driven by a 12.8% increase in the volume of Blood Volume Kits sold (979 kits vs. 868 kits).
Outlook, Risks, and Management Commentary
- Investment Strategy: Management continues to rely on the investment portfolio to subsidize R&D and operations. The portfolio consists primarily of electric utility stocks. The company utilizes short selling and options strategies, which introduced significant volatility in Q1 2009.
- Product Development: The company is conducting clinical trials for the BVA-100 in Intensive Care, Heart Failure, and Dialysis. A multi-center heart failure study (TEAM HF) is anticipated to begin in July 2009.
- Reimbursement Risk: A CMS policy change effective January 1, 2008, eliminated separate Medicare reimbursement for diagnostic radiopharmaceuticals like Daxor's Volumex. The impact on private insurers remains unclear.
- Supply Chain Risk: Volumex syringes are filled by a single FDA-approved manufacturer. Disruption of this supply would be material to the business.
- Customer Concentration: Four hospital customers accounted for 64.27% of Blood Volume Kit sales in Q1 2009.
Investor Verification Checklist
- Cash Runway: Verify the sufficiency of the $37,612 cash balance against upcoming operating expenses and the $600,000 bank note expiring in May 2009.
- Margin Debt Sustainability: Assess the risk associated with the $17.7 million in margin debt secured by the investment portfolio, particularly given the recent mark-to-market losses.
- Investment Volatility: Review the impact of the $6.26 million mark-to-market loss on short positions and the stability of the utility stock portfolio.
- Reimbursement Trends: Monitor whether private insurers follow the CMS lead in denying separate reimbursement for Volumex kits.
- Clinical Trial Results: Track the publication of the ICU study results (expected Q1 2010) and the initiation of the TEAM HF study.